Fig. 1: Outcomes for second line of therapy.
From: Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomide
A Progression free survival in 2nd line (immediate next line) of therapy. B Overall survival from 2nd line (immediate next line) of therapy.
